New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

WO2017046774A3 - Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis - Google Patents

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis Download PDF

Info

Publication number
WO2017046774A3
WO2017046774A3 PCT/IB2016/055557 IB2016055557W WO2017046774A3 WO 2017046774 A3 WO2017046774 A3 WO 2017046774A3 IB 2016055557 W IB2016055557 W IB 2016055557W WO 2017046774 A3 WO2017046774 A3 WO 2017046774A3
Authority
WO
WIPO (PCT)
Prior art keywords
arteritis
treatment
use
takayasu
prophylaxis
Prior art date
Application number
PCT/IB2016/055557
Other languages
French (fr)
Other versions
WO2017046774A2 (en
Inventor
Kenneth Flanagan
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562219611P priority Critical
Priority to US62/219,611 priority
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of WO2017046774A2 publication Critical patent/WO2017046774A2/en
Publication of WO2017046774A3 publication Critical patent/WO2017046774A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
PCT/IB2016/055557 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis WO2017046774A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201562219611P true 2015-09-16 2015-09-16
US62/219,611 2015-09-16

Publications (2)

Publication Number Publication Date
WO2017046774A2 WO2017046774A2 (en) 2017-03-23
WO2017046774A3 true WO2017046774A3 (en) 2017-05-04

Family

ID=56990687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055557 WO2017046774A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Country Status (1)

Country Link
WO (1) WO2017046774A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015136469A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566D1 (en) 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Tech A process for the preparation of specific binding pair members
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (en) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Powerful homologous promoter from hamsters
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1153365B1 (en) 1999-02-05 2007-08-22 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc Methods for using anti-muc18 antibodies
AT394121T (en) 2001-12-28 2008-05-15 Amgen Fremont Inc Using antibodies to the antigen muc18-
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
EP1567652B1 (en) 2002-11-29 2007-08-22 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
DE10338531A1 (en) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for recloning of production cells
DK1820022T3 (en) 2004-11-10 2009-09-14 Boehringer Ingelheim Pharma The use of flow cytometric analysis in order to optimize cell bank strategies of CHO cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
DK2126093T3 (en) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Improvement of protein production
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015136469A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALEXANDER JARASCH ET AL: "Developability Assessment During the Selection of Novel Therapeutic Antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 104, no. 6, 1 June 2015 (2015-06-01), pages 1885 - 1898, XP055217440, ISSN: 0022-3549, DOI: 10.1002/jps.24430 *
LORICERA JAVIER ET AL: "Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 44, no. 6, 27 December 2014 (2014-12-27), pages 717 - 723, XP029229325, ISSN: 0049-0172, DOI: 10.1016/J.SEMARTHRIT.2014.12.005 *
NOBBMANN ULF ET AL: "Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies.", BIOTECHNOLOGY & GENETIC ENGINEERING REVIEWS 2007, vol. 24, 2007, pages 117 - 128, XP002764345, ISSN: 0264-8725 *
YING ZHANG ET AL: "Generation and Characterization of a Panel of Monoclonal Antibodies Against Distinct Epitopes of Human CD146", HYBRIDOMA, vol. 27, no. 5, 1 October 2008 (2008-10-01), pages 345 - 352, XP055155690, ISSN: 1554-0014, DOI: 10.1089/hyb.2008.0034 *
ZHENG C ET AL: "Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 41, no. 11, 1 November 2009 (2009-11-01), pages 2163 - 2172, XP026644025, ISSN: 1357-2725, [retrieved on 20090405], DOI: 10.1016/J.BIOCEL.2009.03.014 *

Also Published As

Publication number Publication date
WO2017046774A2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
TWI627219B (en) Copolymer formulation for directed self-assembly, methods of manufacture thereof and articles comprising the same
TWI609886B (en) Antibodies, hybridoma for producing the antibodies, pharmaceutical compositions comprising the antibodies and uses thereof
CN105026428A (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TW201446252A (en) Pharmaceutical use of a composition including a carbonaceous material and an active particle
CN106146416B (en) Nitrogen replaces 3- oxo -6- substituted-tetrahydro quinoxaline structural compounds, preparation method and its medical usage
GR1008177B (en) Method for the treatment of fir-based extract exhibiting biological action - use of same for the cure of human and animal diseases
TWI619731B (en) Peptides with antimicrobial, anticancer and/or enhancing wound healing activities, pharmaceutical compositions containing the same and use of the peptides with antimicrobial and/or anticancer activities
Mescheryakova et al. The European Court under Human Rights and Mechanisms Maintenance of the Right to the individual Complaint in Russia
CN302205259S (en) Waist tuck pants
MX2017007519A (en) Myostatin or activin antagonists for the treatment of sarcopenia.
WO2017210617A3 (en) Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3103802A4 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
SG10201804306VA (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
CL2015001791A1 (en) Zinc-Lysine Complex comprising [zn (c6h14n2o2) 2Cl] + Cl-; personal care composition applied to the skin; oral care composition; and method to reduce perspiration and / or body odor; method of preparation of zinc-lysine complex.
CL2017002031A1 (en) Nasal powder formulation for the treatment of hypoglycaemia
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
TW201722987A (en) Polyomavirus neutralizing antibodies
CN107636013A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
WO2017139664A8 (en) Intermediates in the synthesis of eribulin and related methods of synthesis
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
MX2017007338A (en) Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases.
PL411634A1 (en) Pharmaceutical composition containing folic acid and L-5-methyltetrahydrofolic acid calcium salt and its application
UY35602A (en) novel compounds for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770569

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 16770569

Country of ref document: EP

Kind code of ref document: A2